Bispecific Antibodies (Amivantamab EGF plus MET Dual Targeting)

# Bispecific Antibodies (Amivantamab EGF plus MET Dual Targeting)

## Clinical Pearl
If you remember ONE thing, it is that Amivantamab is specifically indicated for Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 insertion mutations, which are notoriously resistant to traditional EGFR tyrosine kinase inhibitors (TKIs). By targeting both EGFR and MET, it overcomes the common MET-amplification bypass resistance mechanism. Clinically, watch out for severe infusion-related reactions (IRRs) on the first dose and dermatologic toxicities.

## Memory Targets
- Amivantamab is indicated for EGFR Exon 20 insertion mutations.
- MET amplification is a primary bypass resistance mechanism to EGFR inhibitors.
- High incidence of Infusion-Related Reactions (IRR), especially on the first day of treatment.
- Mechanism of action includes trogocytosis (macrophages 'nibbling' the receptor complex).
- Causes significant dermatologic toxicity (rash, paronychia) due to wild-type EGFR inhibition.

## Process Steps
undefined. EGFR and MET receptors are active on the tumor cell surface, driving downstream MAPK/PI3K signaling.
undefined. Amivantamab binds to the extracellular domains of both EGFR and MET simultaneously.
undefined. Ligand binding is blocked, halting downstream MAPK/PI3K signaling cascades.
undefined. The Fc portion of Amivantamab recruits Immune Effector Cells (Macrophages and NK cells) to the tumor cell.
undefined. Immune cells induce trogocytosis (receptor downmodulation) and ADCC, leading to tumor cell death.

## Phonetic & Etymology Clues
Amivantamab: Ammo (Ami) + Van (van) + Two (ta) + Mab (Y-shaped antibody) = An 'Ammo Van' delivering a dual-headed Y-wrench,EGFR: Egg (E) + Green (G) + Faucet (F) + Ring (R) = An Egg-shaped Green Faucet,MET: Metal (Met) = A heavy Metal backup faucet,Trogocytosis: Trough (Trogo) + Cell (cyto) = Eating from a trough (nibbling bites out of the pipe)

## Entity Summary
- **Amivantamab**: A fully human bispecific monoclonal antibody that simultaneously binds to the extracellular domains of both EGFR and MET. → Epidermal Growth Factor Receptor (EGFR), Mesenchymal-Epithelial Transition factor (MET), Immune Effector Cells (Macrophages/NK Cells)
- **Epidermal Growth Factor Receptor (EGFR)**: A receptor tyrosine kinase that, when mutated (e.g., Exon 20 insertions), drives uncontrolled tumor cell proliferation. → Amivantamab, Downstream Signaling Kinases (MAPK/PI3K)
- **Mesenchymal-Epithelial Transition factor (MET)**: A receptor tyrosine kinase that often amplifies or activates as a bypass resistance mechanism when EGFR is inhibited. → Amivantamab, Downstream Signaling Kinases (MAPK/PI3K)
- **Downstream Signaling Kinases (MAPK/PI3K)**: Intracellular signaling cascades that promote cell survival and proliferation when activated by EGFR or MET. → Epidermal Growth Factor Receptor (EGFR), Mesenchymal-Epithelial Transition factor (MET)
- **Immune Effector Cells (Macrophages/NK Cells)**: Immune cells that recognize the Fc portion of Amivantamab, leading to antibody-dependent cellular cytotoxicity (ADCC) and trogocytosis (receptor degradation). → Amivantamab

If you remember ONE thing, it is that Amivantamab is specifically indicated for Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 insertion mutations, which are notoriously resistant to traditional EGFR tyrosine kinase inhibitors (TKIs). By targeting both EGFR and MET, it overcomes the common MET-amplification bypass resistance mechanism. Clinically, watch out for severe infusion-related reactions (IRRs) on the first dose and dermatologic toxicities.